LIVANOVA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.07 USD | +0.39% |
|
+2.47% | +18.03% |
| May. 01 | LivaNova's Q1 Adjusted Earnings, Revenue Rise, Tops Street View; Raises 2024 Guidance | MT |
| May. 01 | Transcript : LivaNova PLC, Q1 2024 Earnings Call, May 01, 2024 |
Financials (USD)
| Sales 2024 * | 1.22B | Sales 2025 * | 1.28B | Capitalization | 3.31B |
|---|---|---|---|---|---|
| Net income 2024 * | 39M | Net income 2025 * | 91M | EV / Sales 2024 * | 2.64 x |
| Net cash position 2024 * | 102M | Net cash position 2025 * | 231M | EV / Sales 2025 * | 2.41 x |
| P/E ratio 2024 * |
88.8
x | P/E ratio 2025 * |
35.7
x | Employees | 2,900 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on LivaNova PLC
More recommendations
More news
| 1 day | +0.39% | ||
| 1 week | +2.47% | ||
| 1 month | -2.48% | ||
| 3 months | +10.55% | ||
| 6 months | +32.99% | ||
| Current year | +18.03% |
1 week
59.36
61.94
1 month
58.7664.48
Current year
47.7964.48
1 year
42.7564.48
3 years
40.2693.89
5 years
33.4093.89
10 years
33.40131.54
| Managers | Title | Age | Since |
|---|---|---|---|
Alex Shvartsburg
DFI | Director of Finance/CFO | 54 | 16-12-31 |
William Kozy
CHM | Chairman | 72 | 18-06-11 |
Matt J. Dodds
CTO | Chief Tech/Sci/R&D Officer | - | 18-01-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 20-12-02 | |
Peter Wilver
BRD | Director/Board Member | 64 | 22-06-12 |
William Kozy
CHM | Chairman | 72 | 18-06-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.19% | 430 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 61.07 | +0.39% | 289,945 |
| 24-05-30 | 60.83 | +0.60% | 301,138 |
| 24-05-29 | 60.47 | +0.72% | 351,705 |
| 24-05-28 | 60.04 | +0.74% | 471,326 |
| 24-05-24 | 59.6 | +0.37% | 403,727 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Companyâs next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
Calendar
2024-06-10
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
61.07
USD
Average target price
69.2
USD
Spread / Average Target
+13.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.03% | 3.31B | |
| -7.16% | 178B | |
| -1.23% | 107B | |
| -4.86% | 67.04B | |
| -4.29% | 47.24B | |
| +10.32% | 44.62B | |
| +8.14% | 42.5B | |
| +15.76% | 29.99B | |
| +15.53% | 25.22B | |
| -5.88% | 24.14B |
- Stock Market
- Equities
- LIVN Stock
